Maze Therapeutics, Inc.
MAZE
$13.31
-$0.18-1.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 2.50M | 165.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 2.50M | 165.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 0.00 | 2.50M | 165.00M |
| SG&A Expenses | 8.37M | 7.82M | 7.51M | 6.87M | 5.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.47M | 35.40M | 29.73M | 26.73M | 25.45M |
| Operating Income | -36.47M | -35.40M | -29.73M | -24.23M | 139.56M |
| Income Before Tax | -33.68M | -32.79M | -29.85M | -25.03M | 140.78M |
| Income Tax Expenses | -- | -- | -275.00K | -279.00K | 1.73M |
| Earnings from Continuing Operations | -33.68M | -32.79M | -29.58M | -24.75M | 139.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.68M | -32.79M | -29.58M | -24.75M | 139.06M |
| EBIT | -36.47M | -35.40M | -29.73M | -24.23M | 139.56M |
| EBITDA | -35.83M | -34.72M | -29.02M | -23.44M | 140.41M |
| EPS Basic | -0.77 | -1.15 | -2.02 | -1.00 | 5.92 |
| Normalized Basic EPS | -0.48 | -0.72 | -7.25 | -5.76 | 36.77 |
| EPS Diluted | -0.77 | -1.15 | -2.31 | -1.00 | 3.22 |
| Normalized Diluted EPS | -0.48 | -0.72 | -7.25 | -5.76 | 20.36 |
| Average Basic Shares Outstanding | 43.80M | 28.63M | 2.43M | 2.43M | 2.39M |
| Average Diluted Shares Outstanding | 43.80M | 28.63M | 2.43M | 2.43M | 4.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |